ECSP099602A - Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas - Google Patents

Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas

Info

Publication number
ECSP099602A
ECSP099602A EC2009009602A ECSP099602A ECSP099602A EC SP099602 A ECSP099602 A EC SP099602A EC 2009009602 A EC2009009602 A EC 2009009602A EC SP099602 A ECSP099602 A EC SP099602A EC SP099602 A ECSP099602 A EC SP099602A
Authority
EC
Ecuador
Prior art keywords
phenyl
acid
forms
isoxazol
formulations
Prior art date
Application number
EC2009009602A
Other languages
English (en)
Inventor
Holger Petersen
Christoph Krell
Michael Mutz
Brian William Dymock
Weijia Zheng
Martin James Drysdale
Original Assignee
Novartis Ag
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099602(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Vernalis R&D Ltd filed Critical Novartis Ag
Publication of ECSP099602A publication Critical patent/ECSP099602A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevas formas de sal de etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, en particular la sal de mesilato, clorhidrato, tartrato, fosfato, y hemi-fumarato de la misma; a formas cristalinas de estas sales; a polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico; a hidratos y polimorfos de las nuevas formas de sal mencionadas anteriormente; al uso de las nuevas formas de sal mencionadas anteriormente, para la fabricación de un medicamento para el tratamiento de un trastorno mediado por Hsp90; a un método para el tratamiento de un trastorno mediado por Hsp90, utilizando las nuevas formas de sal; a formulaciones que comprenden estas formas de sal, en particular soluciones acuosas adecuadas para administración intravenosa; y a recipientes de vidrio ámbar que se rellenan con estas formulaciones.
EC2009009602A 2007-03-01 2009-08-28 Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas ECSP099602A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01

Publications (1)

Publication Number Publication Date
ECSP099602A true ECSP099602A (es) 2009-12-28

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009602A ECSP099602A (es) 2007-03-01 2009-08-28 Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas

Country Status (40)

Country Link
US (3) US8163747B2 (es)
EP (2) EP2131845B1 (es)
JP (1) JP2010520176A (es)
KR (1) KR20090122218A (es)
CN (2) CN101636162A (es)
AR (1) AR065519A1 (es)
AT (1) ATE552836T1 (es)
AU (1) AU2008220800B2 (es)
BR (1) BRPI0807992A2 (es)
CA (1) CA2678043A1 (es)
CL (1) CL2008000618A1 (es)
CO (1) CO6210828A2 (es)
CR (1) CR10989A (es)
CY (1) CY1113805T1 (es)
DK (1) DK2131845T3 (es)
DO (1) DOP2009000209A (es)
EA (1) EA017075B1 (es)
EC (1) ECSP099602A (es)
ES (1) ES2384906T3 (es)
GE (1) GEP20115309B (es)
GT (1) GT200900236A (es)
HR (1) HRP20120535T1 (es)
IL (1) IL200401A0 (es)
MA (1) MA31204B1 (es)
MX (1) MX2009009233A (es)
NI (1) NI200900161A (es)
NZ (1) NZ578854A (es)
PA (1) PA8771101A1 (es)
PE (1) PE20090166A1 (es)
PL (1) PL2131845T3 (es)
PT (1) PT2131845E (es)
RS (1) RS52351B (es)
SI (1) SI2131845T1 (es)
SM (1) SMAP200900080A (es)
TN (1) TN2009000357A1 (es)
TW (1) TW200844102A (es)
UA (1) UA101950C2 (es)
UY (1) UY30943A1 (es)
WO (1) WO2008104595A1 (es)
ZA (1) ZA200905417B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
WO2010060854A1 (en) 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
JP5845193B2 (ja) * 2010-01-21 2016-01-20 アプレア エイビー 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液
KR101392086B1 (ko) * 2010-02-17 2014-05-07 일동제약주식회사 신규 5각 헤테로 고리 유도체 및 그 제조방법
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515726C (en) * 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazole compounds
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
US20100069458A1 (en) 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
AU2008220800A1 (en) 2008-09-04
EP2131845A1 (en) 2009-12-16
EP2545921A2 (en) 2013-01-16
TN2009000357A1 (en) 2010-12-31
NZ578854A (en) 2012-03-30
CN101636162A (zh) 2010-01-27
AU2008220800B2 (en) 2012-02-16
DK2131845T3 (da) 2012-07-16
NI200900161A (es) 2010-07-27
AR065519A1 (es) 2009-06-10
US8163747B2 (en) 2012-04-24
US8487095B2 (en) 2013-07-16
GT200900236A (es) 2011-09-14
CL2008000618A1 (es) 2008-09-12
UA101950C2 (ru) 2013-05-27
CY1113805T1 (el) 2016-07-27
PE20090166A1 (es) 2009-03-14
EP2545921A3 (en) 2013-04-10
PL2131845T3 (pl) 2012-09-28
KR20090122218A (ko) 2009-11-26
UY30943A1 (es) 2008-10-31
US20100093732A1 (en) 2010-04-15
EP2131845B1 (en) 2012-04-11
CA2678043A1 (en) 2008-09-04
CN102302500A (zh) 2012-01-04
MA31204B1 (fr) 2010-02-01
EA017075B1 (ru) 2012-09-28
JP2010520176A (ja) 2010-06-10
PA8771101A1 (es) 2009-02-09
MX2009009233A (es) 2010-06-02
ES2384906T3 (es) 2012-07-13
GEP20115309B (en) 2011-10-25
EA200901141A1 (ru) 2010-04-30
TW200844102A (en) 2008-11-16
PT2131845E (pt) 2012-07-10
WO2008104595A1 (en) 2008-09-04
IL200401A0 (en) 2010-04-29
HRP20120535T1 (hr) 2012-07-31
SMAP200900080A (it) 2010-01-19
CO6210828A2 (es) 2010-10-20
BRPI0807992A2 (pt) 2014-06-17
ATE552836T1 (de) 2012-04-15
DOP2009000209A (es) 2009-09-15
ZA200905417B (en) 2010-05-26
CR10989A (es) 2010-03-01
SI2131845T1 (sl) 2013-02-28
US20120172592A1 (en) 2012-07-05
RS52351B (sr) 2012-12-31
HK1139073A1 (en) 2010-09-10
US20130296556A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
CY1122565T1 (el) Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης
MY149731A (en) Compounds
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
MX383551B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
CY1125224T1 (el) Κρυσταλλικες μορφες 1-(3-τριτ-βουτυλο-1-ρ- τολυλο-1η-πυραζολ-5-υλο)-3-(5-φθορο-2-(1-(2- υδροξυαιθυλ)-ινδαζολ-5-υλοξυ)βενζυλ)ουριας υδροχλωρικη
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
BR112015006243A2 (pt) agentes antibacterianos de fenicol
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
TH156839A (th) รูปแบบที่เป็นผลึกของ 1-(3-เทอร์ท-บิวทิล-1-พี-โทลิล-1เอช-ไพราซอล-5-อิล)-3-(5-ฟลูออโร-2-(1-(2-ไฮดรอกซีเอทิล)-1เอช-อินดาซอล-5-อิลอกซี)เบนซิล)ยูเรียไฮโดรคลอไรด์
NZ752587B2 (en) Lsd1 inhibitors and medical uses thereof
TH146336A (th) สารประกอบไพริดาซิโนนและการใช้สารดังกล่าวเป็นสารยับยั้ง daao
UA103803C2 (en) Use of 1-methoxycarbonylmethyl-7-bromo-5-phenyl-3-arylamino-1,2-dihydro-3h-1,4-benzodiazepine-ones as analgetic agents
AR105922A1 (es) 1-((6-metoxinaftalen-2-il)metil)-4-(3,3,3-trifluoropropanoil)octahidro-1h-2,6-metanopirrolo[3,2-b]piridin-3-il-pivalato útil en el tratamiento de dolor
TH117374A (th) เมแทบอโทรพิค กลูทาเมท รีเซพเตอร์ ไอซอกซาโซล ลิแกนด์ และการใช้สารเหล่านั้นในการบำบัดความผิดปกติทางประสาทวิทยา และทางจิตเวช